HOME >> MEDICINE >> NEWS
ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting

RICHMOND, CALIF. (Monday, May 18, 1998) --- Onyx Pharmaceuticals, Inc. (Nasdaq:ONXX) today reported results from two Phase II studies of its lead anticancer viral therapeutic, ONYX-015, in patients with tumors of the head and neck. In an ongoing Phase II study combining ONYX-015 with standard chemotherapy, the company reported that nine out of ten patients with recurrent tumors have experienced tumor regressions of greater than 50 percent to date, with two patients experiencing complete responses. In addition, the company reported that 30 percent of patients treated with ONYX-015 alone had significant tumor regressions, including two complete regressions in patients with end-stage, treatment-resistant disease.

During a poster session today at the American Society of Clinical Oncology (ASCO) meeting in Los Angeles, Onyx presented interim results from a Phase II trial combining ONYX-015 with Cisplatin and 5-FU, two standard chemotherapeutic agents used in the treatment of head and neck cancers. In addition to the two patients who had complete responses, seven patients experienced between 50 and 95 percent reductions in tumor mass. The one remaining patient has experienced a 40 percent tumor regression. To date, all of the patients continue on treatment with no evidence of disease progression. The average overall response rate with Cisplatin and 5-FU alone is about 35 percent historically in patients with recurrent disease,noted David H. Kirn, M.D., director of clinical research at Onyx.

"We have seen significant tumor regression in the patients treated to date, including some complete responses, and this is a dramatic early finding," Dr. Kirn said. "But we have only evaluated ten patients at this point. While we are encouraged by these initial results, we remain cautiously optimistic."

"Of course, because this is an ongoing study, we do not yet have information regarding durability of responses. We will be able to discuss these findings with gre
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415/ 821-2413
Kureczka/Martin Associates
18-May-1998


Page: 1 2 3

Related medicine news :

1. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
2. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
3. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
4. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
5. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
6. Pharmaceuticals and personal care products
7. Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement
8. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis
9. Beyond Pharmaceuticals: Business And Academic Leaders Forecast The Future Of "Combinatorial Chemistry"
10. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
11. Melanoma Patients Sentinel Lymph Nodes (SLNS) Play A Strong Role In Disease Prognosis, UCSF Study Reports

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/11/2018)... ... ... Dr. Siavash Eftekhari, Oral and Maxillofacial Surgeon at Monarch Dental® in ... to deliver dental care in impoverished communities. Along with a team of fellow ... to help deliver care to over 550 individuals in need. , This outreach was ...
(Date:8/11/2018)... ATLANTA (PRWEB) , ... August 11, 2018 , ... ... winner of a Silver Stevie® Award in the Executive of the Year-Business category ... the world’s premier business awards program. All individuals and organizations worldwide – public ...
(Date:8/9/2018)... ... August 09, 2018 , ... ... by simplifying medication adherence monitoring with Smart-pill bottle and mobile applications, DoseSmart ... the App Orchard. , The DoseSmart medication management and medication adherence platform ...
(Date:8/7/2018)... ... August 07, 2018 , ... Sussex Vision Center, a multi-site optometry practice ... Sussex, OD, founded the practice in Coldwater, and over the last three decades has ... to offer comprehensive eye health services for patients of all ages. , “I ...
(Date:8/3/2018)... ... August 03, 2018 , ... On August 2, 2018 ... proceedings. Mark Sadaka of Sadaka Associates, LLC has been litigating Zostavax injuries ... before the Judicial Panel on Multidistrict Litigation for the thousands of people injured by ...
Breaking Medicine News(10 mins):
(Date:8/3/2018)... ... August 03, 2018 , ... Flexefits, a pioneer in direct -pay, direct access ... allowing participants in Direct Primary Care arrangements to keep HSA eligibility and permit DPC ... individual and $300 per family per month.) , “We are very pleased to see ...
(Date:8/2/2018)... ... ... UMD Professor Utpal Pal leads a team of investigators across multiple institutions ... of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), ... contribute to the spread of major diseases like Lyme disease. Pal is the project ...
(Date:8/2/2018)... ... August 02, 2018 , ... ... with customer relationship management (CRM), patient experience and provider communication solutions for ... Program for Health Information Service Providers (HISPs). DirectTrust is a ...
Breaking Medicine Technology:
Cached News: